IRIS

ASCIERTO, PAOLO ANTONIO

ASCIERTO, PAOLO ANTONIO  

DIPARTIMENTO DI NEUROSCIENZE E SCIENZE RIPRODUTTIVE ED ODONTOSTOMATOLOGICHE  

Mostra records
Risultati 1 - 20 di 678 (tempo di esecuzione: 0.034 secondi).
Titolo Tipologia Data di pubblicazione Autore(i) File
Molecular Pathogenesis of Melanoma: Established and Novel Pathways 2.1 Contributo in volume (Capitolo o Saggio) 2012 Ascierto, P; Ascierto, Ml; Capone, M; Elaba, Z; Murphy, Mj; And Palmieri, G
CD40 activation as potential tool in malignant neoplasms 1.1 Articolo in rivista 2002 Ottaiano, A; Pisano, C; De Chiara, A; Ascierto, P; Botti, G; Barletta, E; Apice, G; Gridelli, C; Iaffaioli, Vr
Expanded access programmes: patient interests versus clinical trial integrity 1.1 Articolo in rivista 2015 Ascierto, P
Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group 1.1 Articolo in rivista 2003 Ascierto, P
Computer-aided diagnosis of melanocytic lesions 1.1 Articolo in rivista 2005 Ascierto, P
Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study 1.1 Articolo in rivista 2017 Ascierto, P
Soluble interleukin-2 receptor in stage I-III melanoma 1.1 Articolo in rivista 2006 Ascierto, P
Prognostic value of serum VEGF in melanoma patients: a pilot study 1.1 Articolo in rivista 2004 Ascierto, P
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial 1.1 Articolo in rivista 2012 Long, Gv; Trefzer, U; Davies, Ma; Kefford, Rf; Ascierto, P; Chapman, Pb; Puzanov, I; Hauschild, A; Robert, C; Algazi, A; Mortier, L; Tawbi, H; Wilhelm, T; Zimmer, L; Switzky, J; Swann, S; Martin, Am; Guckert, M; Goodman, V; Streit, M; Kirkwood, Jm; Schadendorf, D.
Temozolomide and cisplatin in avdanced malignant melanoma 1.1 Articolo in rivista 2005 Ascierto, P
Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression 1.1 Articolo in rivista 1999 Palmieri, G; Strazzullo, M; Ascierto, P; Satriano, Smr; Daponte, A; Castello, G
Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay 1.1 Articolo in rivista 2001 Palmieri, G; Ascierto, P; Cossu, A; Mozzillo, N; Motti, Ml; Satriano, Smr; Botti, G; Caraco, C; Celentano, E; Satriano, Ra; Lissia, A; Tanda, F; Pirastu, M
Temozolomide and cisplatin in avdanced malignant melanoma 1.1 Articolo in rivista 2005 Daponte, A; Ascierto, P; Gravina, A; Melucci, M; Scala, S; Ottaiano, A; Simeone, E; Palmieri, G; Comella, G
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma 1.1 Articolo in rivista 2018 Ascierto, P
Effect of nivolumab on health-related quality of life in patients with treatment-na < ve advanced melanoma: results from the phase III CheckMate 066 study 1.1 Articolo in rivista 2016 Ascierto, P
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial 1.1 Articolo in rivista 2015 Ascierto, P
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma 1.1 Articolo in rivista 2015 Ascierto, P
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial 1.1 Articolo in rivista 2015 Ribas, A; Puzanov, I; Dummer, R; Schadendorf, D; Hamid, O; Robert, C; Hodi, Fs; Schachter, J; Pavlick, Ac; Lewis, Kd; Cranmer, Ld; Blank, Cu; O'Day, Sj; Ascierto, P; Salama, Aks; Margolin, Ka; Loquai, C; Eigentler, Tk; Gangadhar, Tc; Carlino, Ms; Agarwala, Ss; Moschos, Sj; Sosman, Ja; Goldinger, Sm; Shapira-Frommer, R; Gonzalez, R; Kirkwood, Jm; Wolchok, Jd; Eggermont, A; Li, Xn; Zhou, W; Zernhelt, Am; Lis, J; Ebbinghaus, S; Kang, Sp; Daud, A
miR-579-3p controls melanoma progression and resistance to target therapy 1.1 Articolo in rivista 2016 Ascierto, P
Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials 1.1 Articolo in rivista 2016 Ascierto, P